GeNeuro Archives

News and Trends 17 Sep 2019

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, […]

September 17, 2019 - 4 minutesmins - By Jonathan Smith

geneuro multiple sclerosis neuron viral dna

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

More News! 26 Mar 2018

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been in our genome since ancient times. Paris-based biotech GeNeuro has reported that a treatment it is developing in partnership with Servier has potential to treat […]

March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

multiple sclerosis antibody CIDP geneuro 1

News and Trends 26 Feb 2018

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro develops therapies targeting factors encoded by human endogenous retroviruses that are implicated in neurological and autoimmune disorders. The biotech’s drug, GNbAC1, which is being developed for multiple […]

February 26, 2018 - 2 minutesmins - By Alex Dale

More News! 1 Nov 2017

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […]

November 1, 2017 - 2 minutesmins - By Evelyn Warner

geneva biotech serono university of geneva

Best in Biotech 30 May 2017

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […]

May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us